Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / July / Gene Therapy Successes
Insights Glaucoma Health Economics and Policy Retina

Gene Therapy Successes

Ophthalmology is quietly becoming gene therapy’s next big frontier. Here’s how the science, the patients, and the regulations are aligning.

By Daniel Eisenman 7/7/2025 4 min read

Share

In recent years, ophthalmology has emerged as one of the most promising frontiers in gene therapy. The eye's unique characteristics – coupled with increasing research efforts into the field – are leading to promising treatments for a variety of genetic eye diseases previously considered untreatable. The potential impact is expansive, too. Once researchers establish the principle that works, the same technique can be applied to many eye diseases, not just those caused by genetic mutations. For example, gene therapy has shown promise to treat acquired retinal diseases, such as glaucoma, that have a complex origin.

Eyes are well-suited for cell and gene therapy for a variety of reasons. First, the eye’s immune system is relatively tolerant (although there have been cases where gene therapy can cause inflammation requiring steroid treatment), making it easier to introduce and maintain gene therapies. Second, it is easily accessible for diagnosis, treatment, and observation, allowing for non-invasive monitoring of treatment efficacy. Third, the eye’s unique structure allows for localized delivery of therapies to specific tissues, such as the retina. And fourth, the ocular barriers separate the eyes from the rest of the body, limiting the immune response in the eye and protecting other tissues.

Given these conditions, it is not surprising that there were 159 gene therapy clinical trials targeting ophthalmic disorders up to the end of 2022, with the majority focusing on retinal and optic nerve disorders. While most ophthalmology gene therapies studies use genetically engineered viruses to deliver therapeutic genes to the eyes, in March 2025 the FDA approved the first gene-modified cellular therapy product for ophthalmology: Neurotech Pharmaceuticals’ cell therapy for macular telangiectasia type 2 (MacTel). The drug, Encelto, is delivered in a tiny implanted membrane that encapsulates the retinal pigment epithelial cell, which has been genetically engineered to express the protein ciliary neurotrophic factor. That protein helps photoreceptors in the eye survive longer, slowing down the disease.

Envisioning a bright future

The cell and gene therapy market today is calculated at about $25 billion, and projected to reach $117.46 billion by 2034, growing at a CAGR of 18.7 percent from 2025 to 2034. The rapid growth is driven by an increasing burden of cancer and other targeted diseases, rapidly expanding research and robust pipeline, substantial funding by venture capitalists, and technological innovations. Ophthalmology is poised to capture the biggest share of that growth after oncology, with ophthalmic drugs anticipated to expand at a significant CAGR of 12.8 percent during this same period – especially with the growing emphasis on developing targeted gene therapies.

While growing at a rate that inspires hope, gene therapy for eye diseases is still in its infancy. Formidable challenges, including unpredictable immune responses, and long-term safety and efficacy, persist. Increased clinical research is exciting, but the industry must maintain the utmost care. Site experience with small molecules and antibodies, for instance, is vastly different compared to gene therapy expertise. Unique and significant health risks demand proper safety practices not only for patients, but for everyone associated with the trial – and this starts before a single patient enrolls with the independent biosafety reviews. By investing time and resources in cell and gene therapies for ophthalmology diseases, we can envision a brighter, healthier future for all.

About the Author(s)

Daniel Eisenman

Daniel Eisenman is Executive Director of Biosafety Services at Advarra where he directs the Institutional Biosafety Committee (IBC) and biosafety consulting services, helping researchers navigate regulatory requirements to ensure research is conducted safely and with minimal regulatory delay.

More Articles by Daniel Eisenman

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: